U.S. Department of Health and Human Services-Pharmaceuticals & Healthcare-Deals and Alliances Profile
May 2017
186
About the Report
About the Report
Summary
U.S. Department of Health and Human Services (HHS) is a healthcare service provider that offers patient care and support services. The organization's service areas include health insurance marketplace, mental health, food safety, fighting HIV or AIDS, supporting military families, statistics, medicare fraud, and flu prevention. It also provides social services, prevention and wellness; providers and facilities; public health and safety; and emergency preparedness and response programs. The organization operates in Boston, District of Columbia, Atlanta, Chicago, Kansas City, Dallas, Denver, San Francisco, and Seattle. HHS is headquartered in Washington D.C., the US.
U.S. Department of Health and Human Services-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
Business Description-A brief description of the company's operations.
Key Employees-A list of the key executives of the company.
Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
Key Competitors-A list of the key competitors of the company.
Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
U.S. Department of Health and Human Services, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 11
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15
U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deal Details 31
Venture Financing 31
Aura Biosciences Secures An Additional US$3 Million In Series A Financing 31
Partnerships 31
Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 31
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 32
Oncoceutics Enters into Research Agreement with National Institutes of Health 33
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 34
Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 35
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 36
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 37
Agenus Enters into Agreement with National Cancer Institute 38
Threshold Pharma Enters into Agreement with National Cancer Institute 39
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 39
Immunovia to Enter into Agreement with National Cancer Institute 40
Pfizer Enters into Agreement with National Cancer Institute 41
Epizyme Enters into Research Agreement with National Cancer Institute 42
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 43
Atrin Pharma Enters into Agreement with National Cancer Institute 44
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 44
NewLink Genetics Enters into Agreement with BARDA 45
Riptide Bioscience Enters into Agreement with National Cancer Institute 46
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 46
PapGene Enters into Agreement with National Cancer Institute 47
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 48
Cellerant Therapeutics Enters into Contract with National Institutes of Health 49
The Medicines Company Enters into Agreement with BARDA 49
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 50
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 51
Cellectar Biosciences Enters into Contract with National Cancer Institute 52
University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 53
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 53
Altimmune Enters into Contract Agreement with BARDA for NasoShield 54
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 55
RedHill Biopharma Enters into Agreement with NIAID 56
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 57
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 57
Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 58
Kite Pharma Enters into R&D Agreement with National Cancer Institute 59
Cerus Enters into Contract with Biomedical Advanced Research and Development Authority 59
Flatiron Health Enters into Research Agreement with US Food and Drug Administration 60
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 61
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 62
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 63
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 64
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 64
Eagle Pharma Enters into Agreement with National Institutes of Health 65
Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 66
PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 67
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 68
Regen BioPharma Enters into Research Agreement with National Institutes of Health 68
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 69
OriGene Technologies Enters into Contract with National Cancer Institute 70
SolaranRx Enters into R&D Agreement with National Cancer Institute 71
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 72
Precision Biologics Enters into R&D Agreement with National Cancer Institute 72
Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 73
GlaxoSmithKline Enters into Research Agreement with NIAID 74
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 75
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 76
Vaxart Enters into Contract with BARDA 77
SNBL USA Enters into Contract with BARDA 77
Saint Louis University Enters into Agreement with National Institutes of Health 78
SRI International Enters into Biological Testing Facility Contract with NICHD 79
KIYATEC Enters into Research Contract with National Cancer Institute 80
Vince & Associates Partners with US FDA Office of Generic Drugs 80
Protein Foundry Enters into Research Contract with NHLBI 81
SuviCa Enters into Contract with National Cancer Institute 82
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 83
Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 83
Pharma Product Development Enters into Agreement with BARDA 84
Galena Biopharma Enters into Agreement with National Cancer Institute 85
Regeneron Pharma Enters into Development Agreement with BARDA 86
WiCell Research Institute Enters into Distribution Agreement with NHLBI 86
Etubics Enters into R&D Agreement with National Cancer Institute 87
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 88
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 89
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 90
FirstString Research Enters into R&D Agreement with NCATS 91
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 91
GenVec Enters into Research Agreement with LMIV 92
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 93
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 94
Intrexon Enters into R&D Agreement with National Cancer Institute 94
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 95
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 96
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 97
Lion Biotech Amends Co-Development Agreement with National Cancer Institute 98
MedImmune Enters into Co-Development Agreement with National Cancer Institute 99
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 100
uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 101
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 101
Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 102
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 103
Atox Bio Enters into Contract Agreement with BARDA for AB103 104
Kadmon Enters into R&D Agreement with NIDCR 105
Foamix Enters into Co-Development Agreement with National Eye Institute 106
New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 106
Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 107
Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 108
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 109
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 110
National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 111
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 111
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 113
Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 114
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 114
Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 115
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 116
Delcath Systems Extends Co-Development Agreement With National Cancer Institute 117
FEI Enters Into R&D Agreement With NIH 118
DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 119
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 120
Concert Pharma Enters Into Research Agreement With NIH 121
AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 122
BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 123
Afraxis Enters Into Co-Development Agreement With National Institutes of Health 124
Aura Biosciences Enters Into Research And Development Agreement With NIH 125
Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 126
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 127
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 128
GNS Healthcare Enters Into An Agreement With National Cancer Institute 129
Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 130
New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 131
RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 132
Licensing Agreements 133
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 133
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 134
PaxVax Enters into Licensing Agreement with National Institutes of Health 135
ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 136
Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 136
Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 137
Biologics Resources Enters into Licensing Agreement with National Institutes of Health 138
Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 139
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 140
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 140
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 141
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 142
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 143
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 144
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 144
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 145
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 147
Peptron Enters into Licensing agreement with National Institutes of Health 147
KannaLife Sciences Enters Into Licensing Agreement With NIH 148
Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 149
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 149
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 150
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 151
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 152
Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 153
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 153
KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 154
BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 155
BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 155
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 157
NanoBio Enters Into Licensing Agreement With National Institutes Of Health 157
Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 158
Key Employees 160
Locations And Subsidiaries 161
Head Office 161
Other Locations & Subsidiaries 161
Recent Developments 164
Government and Public Interest 164
Dec 15, 2016: Department of Health and Human Services awards over $50 Million for new health center sites 164
Dec 01, 2016: Castro Announces $5.29M for UTSA Brain Health Research 165
Sep 15, 2016: HHS awards over $87 million for health centers’ IT enhancements 166
Sep 14, 2016: New data show major improvements in health care access, affordability, and quality under the Affordable Care Act 167
Sep 07, 2016: Molina Healthcare Announces Support for HHS’ Efforts to Improve the Marketplace Benefit and Payment Parameters 169
Aug 25, 2016: United States Surgeon General appeals to America’s clinicians to “Turn the Tide” on the prescription drug epidemic 170
Aug 18, 2016: HHS awards more than $100 million to improve health center quality 171
Aug 11, 2016: $10 Million in Grants Targets Community-Based Efforts to Combat Chronic Diseases in the Delta Region 172
Aug 04, 2016: HHS awards more than $8.6 million for Health Centers to Improve Care Coordination and Become Patient-Centered Medical Homes 173
Jul 26, 2016: Secretary Burwell Highlights Bundled Payments, Future of Delivery System Reform in Florida 174
Jul 25, 2016: Important Next Step towards a Better, Smarter, Healthier Medicare: New Payment Models and Rewards for Better Care at Lower Cost 175
Jul 20, 2016: HRSA Awards More Than $149 million to Grow the Nation’s Primary Care Workforce and Expand Health Professions Training 177
Jul 06, 2016: HHS announces new actions to combat opioid epidemic 178
Apr 18, 2016: Diabetes drug, metformin, lowers risk of heart disease deaths better than sulfonylureas 180
Mar 11, 2016: HHS awards $94 million to health centers to help treat the prescription opioid abuse and heroin epidemic in America 182
Product News 183
Feb 25, 2016: Medidata’s Cloud Technology Powers U.S. Government Research on Drug Development Costs 183
Jan 19, 2017: Northwestern University: Clinical Trials Evaluate New Treatment for Anal Cancer 184
Other Significant Developments 185
Dec 05, 2016: CVS Health and HHS Study Finds Proactive Pharmacy-based Outreach Helps Patients Access Needed Medications during a Natural Disaster 185
Appendix 186
Methodology 186
About GlobalData 186
Contact Us 186
Disclaimer 186
List of Figure
List of Figures
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 13
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15
U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17
List of Table
List of Tables
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Key Facts 1
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
U.S. Department of Health and Human Services, Deals By Therapy Area, 2011 to YTD 2017 15
U.S. Department of Health and Human Services, Medical Devices Deals, 2011 to YTD 2017 17
U.S. Department of Health and Human Services, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Aura Biosciences Secures An Additional US$3 Million In Series A Financing 31
Abeome Enters into Research Agreement with Centers for Disease Control and Prevention 31
ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 32
Oncoceutics Enters into Research Agreement with National Institutes of Health 33
Cyprium Therapeutics Enters into Research and Development Agreement with Eunice Kennedy Shriver NICHD 34
Achieve Life Science and OncoGenex Pharma Enter into Partnership with National Institutes of Health 35
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 36
Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 37
Agenus Enters into Agreement with National Cancer Institute 38
Threshold Pharma Enters into Agreement with National Cancer Institute 39
Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 39
Immunovia to Enter into Agreement with National Cancer Institute 40
Pfizer Enters into Agreement with National Cancer Institute 41
Epizyme Enters into Research Agreement with National Cancer Institute 42
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 43
Atrin Pharma Enters into Agreement with National Cancer Institute 44
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 44
NewLink Genetics Enters into Agreement with BARDA 45
Riptide Bioscience Enters into Agreement with National Cancer Institute 46
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 46
PapGene Enters into Agreement with National Cancer Institute 47
Sanofi Pasteur Enters into Contract with US Department of Health and Human Services 48
Cellerant Therapeutics Enters into Contract with National Institutes of Health 49
The Medicines Company Enters into Agreement with BARDA 49
Protein Sciences Enters into Agreement with Biomedical Advanced Research and Development Authority 50
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 51
Cellectar Biosciences Enters into Contract with National Cancer Institute 52
University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 53
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 53
Altimmune Enters into Contract Agreement with BARDA for NasoShield 54
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 55
RedHill Biopharma Enters into Agreement with NIAID 56
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 57
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 57
Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 58
Kite Pharma Enters into R&D Agreement with National Cancer Institute 59
Cerus Enters into Contract with Biomedical Advanced Research and Development Authority 59
Flatiron Health Enters into Research Agreement with US Food and Drug Administration 60
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 61
Basilea Pharmaceutica International Enters into Agreement with Biomedical Advanced Research and Development Authority 62
Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 63
NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 64
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 64
Eagle Pharma Enters into Agreement with National Institutes of Health 65
Asterand Bioscience Enters into Contract Agreement with National Institutes of Health 66
PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 67
New England Research Institutes Enters into Research Agreement with National Heart Lung and Blood Institute 68
Regen BioPharma Enters into Research Agreement with National Institutes of Health 68
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 69
OriGene Technologies Enters into Contract with National Cancer Institute 70
SolaranRx Enters into R&D Agreement with National Cancer Institute 71
Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 72
Precision Biologics Enters into R&D Agreement with National Cancer Institute 72
Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 73
GlaxoSmithKline Enters into Research Agreement with NIAID 74
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 75
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 76
Vaxart Enters into Contract with BARDA 77
SNBL USA Enters into Contract with BARDA 77
Saint Louis University Enters into Agreement with National Institutes of Health 78
SRI International Enters into Biological Testing Facility Contract with NICHD 79
KIYATEC Enters into Research Contract with National Cancer Institute 80
Vince & Associates Partners with US FDA Office of Generic Drugs 80
Protein Foundry Enters into Research Contract with NHLBI 81
SuviCa Enters into Contract with National Cancer Institute 82
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 83
Centers for Disease Control and Prevention Enters into R&D Agreement with Nanomedical Diagnostics 83
Pharma Product Development Enters into Agreement with BARDA 84
Galena Biopharma Enters into Agreement with National Cancer Institute 85
Regeneron Pharma Enters into Development Agreement with BARDA 86
WiCell Research Institute Enters into Distribution Agreement with NHLBI 86
Etubics Enters into R&D Agreement with National Cancer Institute 87
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 88
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 89
Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 90
FirstString Research Enters into R&D Agreement with NCATS 91
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 91
GenVec Enters into Research Agreement with LMIV 92
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 93
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 94
Intrexon Enters into R&D Agreement with National Cancer Institute 94
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 95
Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 96
VistaGen Therapeutics Enters into R&D Agreement with National Institute of Mental Health 97
Lion Biotech Amends Co-Development Agreement with National Cancer Institute 98
MedImmune Enters into Co-Development Agreement with National Cancer Institute 99
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 100
uBiome Enters into Research Agreement with Centers for Disease Control and Prevention 101
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 101
Accelerate Diagnostics Enters into Co-Development Agreement with Centers for Disease Control and Prevention 102
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 103
Atox Bio Enters into Contract Agreement with BARDA for AB103 104
Kadmon Enters into R&D Agreement with NIDCR 105
Foamix Enters into Co-Development Agreement with National Eye Institute 106
New Amsterdam Sciences to Enter into Research Agreement with National Institute of Health 106
Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 107
Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 108
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 109
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 110
National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 111
Kite Pharma Enters Into R&D Agreement With National Cancer Institute For Cellular Immunotherapy Products 111
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 113
Diurnal Extends Cooperative Research and Development Agreement with National Institutes of Health 114
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 114
Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 115
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 116
Delcath Systems Extends Co-Development Agreement With National Cancer Institute 117
FEI Enters Into R&D Agreement With NIH 118
DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 119
Raptor Pharma Enters Into Co-Development Agreement With NIDDK For RP104 120
Concert Pharma Enters Into Research Agreement With NIH 121
AVI BioPharma Enters Into Co-Development Agreement With National Institutes of Health For Exon 50 122
BN ImmunoTherapeutics Expands Co-Development Agreement With National Cancer Institute 123
Afraxis Enters Into Co-Development Agreement With National Institutes of Health 124
Aura Biosciences Enters Into Research And Development Agreement With NIH 125
Genesis Biopharma Enters Into Co-Development Agreement With The National Cancer Institute 126
Pharmacyclics Enters Into Co-Development Agreement With National Cancer Institute For PCI-32765 127
Viamet Pharma Enters Into Co-Development Agreement With National Institutes of Health 128
GNS Healthcare Enters Into An Agreement With National Cancer Institute 129
Amsterdam Molecular Enters Into Cooperative Research and Development Agreement With National Institutes of Health 130
New Zealand Pharma Enters Into Co-Development Agreement With National Human Genome Research Institute For DEX-M74 131
RRD International Enters Into Co-Development Agreement With National Institutes of Health Therapeutics For Rare And Neglected Diseases 132
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 133
NICHD Enters into Licensing Agreement with Cyprium Therapeutics 134
PaxVax Enters into Licensing Agreement with National Institutes of Health 135
ConverGene Enters into Licensing Agreement with National Center for Advancing Translational Sciences 136
Great Lakes Neuroscience Enters into Licensing Agreement with National Institutes of Health 136
Genesis Biopharma Enters Into Patent Licensing Agreement With National Institutes Of Health 137
Biologics Resources Enters into Licensing Agreement with National Institutes of Health 138
Medigen Vaccine Biologics Enters into Licensing Agreement with National Institutes of Health for Dengue Vaccine 139
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 140
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 140
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 141
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 142
Kite Pharma Enters into Licensing Agreement with National Institutes of Health 143
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 144
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 144
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 145
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 147
Peptron Enters into Licensing agreement with National Institutes of Health 147
KannaLife Sciences Enters Into Licensing Agreement With NIH 148
Organic Vaccines Enters into Licensing Agreement with National Institutes of Health 149
Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 149
Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 150
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 151
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 152
Radiation Control Technologies Enters Into Licensing Agreement With National Institutes of Health 153
NIH Center for Regenerative Medicine Enters Into Licensing Agreement With Horizon Discovery For Genesis Technology 153
KannaLife Sciences Enters Into Licensing Agreement With NIH-OTT 154
BioDigitalValley Enters Into Licensing Agreement With National Library of Medicine 155
BN ImmunoTherapeutics Enters Into Licensing Agreement With National Institutes of Health 155
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 157
NanoBio Enters Into Licensing Agreement With National Institutes Of Health 157
Ariadne Genomics Extends Licensing Agreement With NCI For Pathway Studio 158
U.S. Department of Health and Human Services, Key Employees 160
U.S. Department of Health and Human Services, Other Locations 161
U.S. Department of Health and Human Services, Subsidiaries 161
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.